Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an American-based oncology-focused, clinical stage biotechnology company, today announced it has selected Hamilton, Ontario-based Centre for Probe Development and Commercialization (CPDC), a well-respected GMP manufacturing organization specializing in radiopharmaceuticals, as a supplier of the company’s lead phospholipid drug conjugate To read more, please click here
Innovation Showcase highlights growing impact of student-entrepreneurs
Canada needs a strategy to reach its biotech potential
Reliq Health Technologies Inc., a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has signed an agreement with Hamilton Health Sciences and McMaster University in Hamilton, Ontario to pilot its remote patient monitoring and care collaboration solution. The pilot is expected to […]
Start-up Turnstone Biologics Closes USD $41M Financing